Kinfo
Adma Biologics Inc. logo

Adma Biologics Inc.

ADMANASDAQHealthcare·US · USD
$8.97
-0.11 (-1.21%)
Prices as of July 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap2.08B USD
Enterprise value43.85B USD
Trailing P/E13.35
Forward P/E9.10
PEG ratio0.18
Price / sales4.13
Price / book5.40
Profitability
Gross margin70.53%
Operating margin-123.39%
Profit margin32.43%
Return on assets21.99%
Return on equity43.30%
Income (TTM)
Revenue509.86M USD
Gross profit312.42M USD
EBITDA216.89M USD
Net income165.35M USD
Diluted EPS$0.68
Rev. growth (YoY)15.90%
Balance sheet
Total cash55.92B USD
Total debt97.67B USD
Debt / equity110.67
Current ratio6.95
Book value / share$1.68
Cash flow (TTM)
Operating cash flow128.32M USD
Levered free cash flow58.35M USD
Shares & price
Shares outstanding232.29M
Float226.72M
Held by institutions93.94%
Beta0.73
50-day MA$8.65
200-day MA$13.81
52-week high$20.46
52-week low$7.21
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-11-0.33-0.09+72.73%2026-05-060.200.17−15.00%2026-02-250.200.22+10.00%2025-11-260.56-0.62−210.71%2025-11-050.160.16+0.00%
About Adma Biologics Inc.

Adma Biologics Inc. is a commercial biopharmaceutical company specializing in plasma-derived biologics used to treat patients with immune deficiencies and certain infectious disease risks. The company operates an integrated model that spans plasma collection, manufacturing, and commercialization, enabling control over key steps in the supply chain. Its primary business segments are ADMA BioManufacturing, which produces immunoglobulin and related plasma-based therapies, and Plasma Collection Centers, which secure source plasma for its products. Adma Biologics also sells plasma-derived intermediate fractions generated during its FDA-approved manufacturing processes and provides laboratory contracting services, with capabilities that include contract filling, labeling, and packing for select customers. The company serves healthcare providers and patients primarily in the United States, focusing on therapies for individuals with compromised or deficient immune systems who are at elevated risk for infections. Headquartered in Ramsey, New Jersey, Adma Biologics plays a specialized role in the biotechnology and healthcare sectors by supplying targeted plasma-derived therapeutic options.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Adam S. Grossman
Employees
640
Headquarters
Ramsey, NJ, United States

Frequently asked questions about Adma Biologics Inc.